Emergent BioSolutions is no doubt one of the most widely-known biotechnology companies in the BioHealth Capital Region, with numerous locations in Gaithersburg, Baltimore, and beyond. If you’re a follower of Emergent, you’ve probably noticed a change in their corporate look and feel over the past few months.
Emergent BioSolutions was arguably one batch away from being a pandemic hero.
Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates.
Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate.
Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.
Quality assurance is a key function in the biopharma industry that provides a hands-on role in day-to-day operations. It’s a role that allows team members to maintain their fingers on the pulse of the beating heart of a drug manufacturing company. And it’s a role that’s available at one of the biggest drug manufacturing companies in the BioHealth Capital Region.
The solution to finding a career with similar purpose and meaning could await you in the life sciences industries, where we don’t make widgets. We make products that save, protect, enhance, and empower people every day, and we need veterans in our workforce to be successful.
Every month, thousands of military veterans around the world begin their transition out of the military with anywhere between 2 and 20 years of experience in some of the most fast-paced, operationally focused, and regulated environments imaginable. These transitioning service-members and their families all bring an army of benefits to bear for innovative organizations willing to give them a chance.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease, including adults 55 and older and those 18 and older who are immunocompromised.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.
Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines. However, the history of this facility goes back more than two decades.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).
